Meeting
2012 ASCO Annual Meeting
Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma.
Authors
Navneet Dhillon
Emory University, Atlanta, GA
Navneet Dhillon , Anna R Rogers , Keith A. Delman , Derek Maetzold , Kristen M. Oelschlager , Stephen Lyle , Gilchrist L. Jackson , Anthony Greisinger , Douglas Parker , Robert W. Cook , David H. Lawson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8543)
DOI
10.1200/jco.2012.30.15_suppl.8543
Abstract #
8543
Poster Bd #
32A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prognostic significance of the CP-GEP assay combining clinicopathologic factors and gene expression profiling in patients (pts) with AJCC v8 stage I/II cutaneous melanoma (CM).
First Author: Teresa Maria Santos Amaral
Poster
2022 ASCO Annual Meeting
Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC).
First Author: Jose Lutzky
Poster
2022 ASCO Annual Meeting
Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy.
First Author: Samuel Cass
Poster
2019 ASCO Annual Meeting
Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).
First Author: Claus Garbe